Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Emerging strategies for targeting cell adhesion in multiple myeloma.

Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA.

Adv Pharmacol. 2012;65:143-89. doi: 10.1016/B978-0-12-397927-8.00006-3. Review.

PMID:
22959026
[PubMed - indexed for MEDLINE]
2.

Novel therapies in MM: from the aspect of preclinical studies.

Hideshima T, Anderson KC.

Int J Hematol. 2011 Oct;94(4):344-54. doi: 10.1007/s12185-011-0917-5. Epub 2011 Sep 1. Review.

PMID:
21881879
[PubMed - indexed for MEDLINE]
3.

Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC.

Semin Oncol. 2001 Dec;28(6):607-12. Review.

PMID:
11740818
[PubMed - indexed for MEDLINE]
4.

Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials.

Bazzi M, Badros A.

Cancer Biol Ther. 2010 Nov 1;10(9):830-8. Epub 2010 Nov 1. Review.

PMID:
21045554
[PubMed - indexed for MEDLINE]
Free Article
5.

Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.

Neri P, Bahlis NJ.

Curr Cancer Drug Targets. 2012 Sep;12(7):776-96. Review.

PMID:
22671924
[PubMed - indexed for MEDLINE]
6.

Contemporary drug therapies for multiple myeloma.

de la Puente P, Azab AK.

Drugs Today (Barc). 2013 Sep;49(9):563-73. doi: 10.1358/dot.2013.49.9.2020941. Review.

PMID:
24086952
[PubMed - indexed for MEDLINE]
7.

Adhesion molecules--The lifelines of multiple myeloma cells.

Katz BZ.

Semin Cancer Biol. 2010 Jun;20(3):186-95. doi: 10.1016/j.semcancer.2010.04.003. Epub 2010 Apr 21. Review.

PMID:
20416379
[PubMed - indexed for MEDLINE]
8.

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.

Anderson KC.

Exp Hematol. 2007 Apr;35(4 Suppl 1):155-62. Review.

PMID:
17379101
[PubMed - indexed for MEDLINE]
9.

The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.

Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, García-Echeverría C, Zimmermann J, Pandiella A, San Miguel JF.

Br J Haematol. 2008 May;141(4):470-82. doi: 10.1111/j.1365-2141.2008.07049.x. Epub 2008 Mar 12.

PMID:
18341634
[PubMed - indexed for MEDLINE]
10.

Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.

Siegel DS.

Semin Hematol. 2012 Jul;49 Suppl 1:S3-15. doi: 10.1053/j.seminhematol.2012.05.005.

PMID:
22727390
[PubMed - indexed for MEDLINE]
11.

Targeting multiple myeloma cells and their bone marrow microenvironment.

Pagnucco G, Cardinale G, Gervasi F.

Ann N Y Acad Sci. 2004 Dec;1028:390-9. Review.

PMID:
15650264
[PubMed - indexed for MEDLINE]
12.

Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.

Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC.

Mol Cancer Ther. 2002 Aug;1(10):851-60.

PMID:
12492118
[PubMed - indexed for MEDLINE]
Free Article
13.

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.

Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jäger D, Olson DL, Sattler M, Chauhan D, Anderson KC.

Br J Haematol. 2011 Nov;155(4):438-48. doi: 10.1111/j.1365-2141.2011.08864.x. Epub 2011 Sep 19.

PMID:
21923653
[PubMed - indexed for MEDLINE]
14.

The evolution and impact of therapy in multiple myeloma.

Laubach JP, Richardson PG, Anderson KC.

Med Oncol. 2010 Jun;27 Suppl 1:S1-6. doi: 10.1007/s12032-010-9442-2. Epub 2010 Feb 19. Review.

PMID:
20169425
[PubMed - indexed for MEDLINE]
15.

Novel targets and derived small molecule inhibitors in multiple myeloma.

Podar K.

Curr Cancer Drug Targets. 2012 Sep;12(7):797-813. Review.

PMID:
22671928
[PubMed - indexed for MEDLINE]
16.

Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.

Riedel SS, Mottok A, Brede C, Bäuerlein CA, Jordán Garrote AL, Ritz M, Mattenheimer K, Rosenwald A, Einsele H, Bogen B, Beilhack A.

PLoS One. 2012;7(12):e52398. doi: 10.1371/journal.pone.0052398. Epub 2012 Dec 26.

PMID:
23300660
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Novel biologically based therapeutic strategies in myeloma.

Gupta D, Hideshima T, Anderson KC.

Rev Clin Exp Hematol. 2002 Sep;6(3):301-24. Review.

PMID:
12616700
[PubMed - indexed for MEDLINE]
18.

Treatment of multiple myeloma: 2009 update.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):263-6.

PMID:
20025098
[PubMed - indexed for MEDLINE]
19.

Emerging therapies for multiple myeloma.

Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC.

Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278 . Review.

PMID:
19249983
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk